Welcome to our dedicated page for IDEX SEC filings (Ticker: IEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to IDEX Corporation (NYSE: IEX) SEC filings, offering investors a primary source of regulatory information about the global engineered products company. IDEX files a variety of documents with the U.S. Securities and Exchange Commission that detail its financial performance, segment results, capital allocation decisions and governance matters.
Through Forms 10-K and 10-Q, investors can review consolidated and segment-level data for the Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety / Diversified Products segments, along with discussions of pricing, volume trends, acquisitions and non-GAAP measures such as organic sales, adjusted EBITDA and free cash flow. Current reports on Form 8-K, several of which are reflected in the recent filings list, disclose material events including quarterly earnings announcements, changes in executive leadership, and share repurchase authorizations.
Filings also identify IDEX’s common stock listing on the New York Stock Exchange under the symbol IEX and provide details on items such as dividend declarations, capital structure and certain compensation arrangements for senior executives. For those monitoring insider activity, Forms 3, 4 and 5 (when available) show transactions by directors and officers in IDEX equity.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand segment performance, major risks, capital deployment and notable governance changes. Real-time updates from EDGAR ensure that new IDEX filings, from quarterly reports to event-driven 8-Ks, appear promptly, giving investors and researchers an efficient way to follow the regulatory record behind IEX stock.
IDEX Corporation has announced a leadership change in its strategy function. On February 4, 2026, the company notified Roopa Unnikrishnan, its Senior Vice President, Chief Strategy and Innovation Officer and a current named executive officer, that her position will be eliminated effective February 28, 2026.
IDEX expects to enter into a separation agreement with Ms. Unnikrishnan under the termination-without-cause terms set out in her existing letter agreement, as previously described in the company’s proxy statement filed in March 2025. The filing does not describe broader organizational changes beyond this role elimination.
A shareholder of IEX has filed a Rule 144 notice to sell up to 14,150 common shares. The filing lists an aggregate market value of $674,916.94 for these shares, to be sold through UBS Financial Services Inc. on the NYSE, with an approximate sale date of 02/06/2026.
The notice states the shares were acquired on 02/06/2026 via a stock option release from the issuer, in the same amount of 14,150 shares. The document also notes that 74,849,436 shares of this class are outstanding, providing context for the potential sale size.
IDEX Corporation filed a current report to share that it has issued a press release announcing its financial results for the period ended December 31, 2025. The press release, dated February 4, 2026, is furnished as Exhibit 99.1 to the report.
The company notes that the information in this item, including the press release, is being furnished rather than filed, which limits its exposure to certain Exchange Act liabilities and controls how it may be incorporated by reference into other securities filings.
IDEX Corporation reported an equity grant to its senior vice president and chief financial officer, Sean M. Gillen. On 01/05/2026, he received 16,595 shares of common stock at a price of $0 per share as an equity award. These are restricted shares that vest in three substantially equal annual installments on each of the first, second and third anniversaries of the grant date, conditioned on his continued employment through each vesting date. Following this award, Gillen beneficially owns 16,595 shares of IDEX common stock in direct form.
IDEX Corporation insider Sean M. Gillen, SVP and Chief Financial Officer, filed an initial ownership report showing no beneficial ownership of company securities. The Form 3 indicates that, as of the event date of January 5, 2026, there are no non-derivative or derivative securities of IDEX Corp reported as beneficially owned by this officer.
IDEX Corporation announced that Sean M. Gillen will become Senior Vice President and Chief Financial Officer effective January 5, 2026, succeeding interim CFO Akhil Mahendra, who will return to his role as Vice President, Corporate Development. Gillen joins from AAR CORP., where he has been Senior Vice President and CFO since 2019, and previously held finance and investment banking roles at USG Corporation and Goldman Sachs.
Under an offer letter dated December 1, 2025, Gillen will receive a base salary of $625,000, target annual cash incentive equal to 85% of base salary starting with the 2026 program, and an annual equity grant targeted at $2,000,000. He will also receive a one-time restricted stock award valued at $3,000,000 that vests over three years and a cash sign-on bonus of $325,000, subject to repayment if he departs or is terminated for cause within 12 months. Severance protections include one year of base salary and target bonus if terminated without cause, increasing to two times those amounts if this occurs within 24 months after a change in control. IDEX also disclosed that Melissa S. Flores, Senior Vice President and Chief Human Resources Officer, will resign effective December 19, 2025 to pursue another opportunity.
IDEX Corporation (IEX) filed a Form 4 reporting an insider purchase. A company director bought 600 shares of common stock on 11/05/2025 at a weighted average price of $169.4112. Following the transaction, the director beneficially owns 6,351 shares, held directly.
The filing notes the trade was executed in multiple lots with prices ranging from $169.35 to $169.43. The weighted average reflects those individual executions, and the reporting person undertakes to provide the specific trade breakdown upon request.
IDEX Corporation (IEX) reported higher quarterly results. For the three months ended September 30, 2025, net sales were $878.7 million, up from $798.2 million, with operating income of $185.8 million versus $168.0 million. Diluted EPS was $1.70 compared with $1.57 a year ago.
Nine-month results were mixed: net sales rose to $2,558.4 million from $2,405.9 million, while net income attributable to IDEX was $354.9 million versus $381.8 million, and diluted EPS was $4.70 versus $5.02. Operating cash flow reached $470.9 million. The company repurchased $175.0 million of common stock year to date and declared a quarterly dividend of $0.71 per share.
Health & Science Technologies led growth, with Q3 revenue of $380.1 million (from $309.9 million), aided by acquisitions. IDEX completed the acquisition of Micro‑LAM for total consideration of $81.9 million and ended the quarter with cash and cash equivalents of $593.8 million and total borrowings of $1,911.8 million, including $310.6 million drawn on its revolving facility.
IDEX Corporation furnished an Item 2.02 Form 8‑K announcing quarterly results for the period ended September 30, 2025. The company issued a press release, provided as Exhibit 99.1, on October 29, 2025. This information is being furnished and is not deemed filed under the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL tags.
IDEX Corporation disclosed that its Board of Directors authorized an additional $635 million for repurchases of the company’s common shares. When combined with approximately $365 million remaining under prior authorizations, the company now has a total share repurchase authorization of about $1 billion.
The company states that repurchases may occur from time to time through open market or privately negotiated transactions and may also be executed under Rule 10b5-1 plans. Management will determine the timing, volume and nature of repurchases based on market conditions, cash investment priorities, applicable securities laws and other factors, and the program can be suspended or discontinued at any time.